Daijiworld Media Network - New Delhi
New Delhi, Feb 23: Vefa Lifesciences has announced the launch of Neurovorin-15, a Leucovorin Calcium (Folinic Acid) formulation, in India, marking a significant milestone in its efforts to advance neurological wellness through science-driven and evidence-based therapeutic solutions.
Leucovorin Calcium is a biologically active form of folate that plays a key role in folate metabolism. It is increasingly being evaluated in clinical settings where Folate Receptor Autoantibody (FRAA) positivity and cerebral folate deficiency are suspected. In children with autism spectrum disorder, disruptions in folate pathways have drawn growing scientific and clinical attention, particularly in cases where conventional folic acid utilisation may be compromised.
With this launch, the company aims to support clinicians by offering a globally benchmarked Leucovorin Calcium formulation manufactured in compliance with stringent quality and safety standards. The company stated that its approach is grounded in scientific evidence, ethical practices and responsible communication, aligned with India’s regulatory framework for prescription-based therapies.
Beyond its pharmaceutical and nutritional portfolio, Vefa Lifesciences has also focused on promoting neurodiversity and social inclusion. Through its “Art for Autism” initiative, the company has sought to create awareness, acceptance and creative empowerment for individuals with Autism.
Last year, the company received the CMPL National Award for introducing India’s first time-release melatonin gummies formulation, reflecting its innovation-driven and patient-centric approach.
Commenting on the launch, B B Nanda, CEO of Vefa Lifesciences, said the company remains committed to developing globally aligned formulations aimed at supporting the overall development and quality of life of individuals living with neurological conditions. He added that the launch of Leucovorin Calcium strengthens the company’s long-term vision of integrating scientific rigour with compassion and social responsibility.
Sharing his clinical perspective, Dr Deepak Gupta, Senior Consultant in Child and Adolescent Psychiatry at Sir Ganga Ram Hospital and Founder and Director of the Centre for Child and Adolescent Wellbeing (CCAW), said Leucovorin has shown promising results in clinical practice.
“Leucovorin is a promising molecule, and we have been using it in clinical practice for several years. In our experience, it has shown encouraging outcomes in areas such as cognition, speech and language in children with Autism Spectrum Disorder,” he said.
Dr Gupta also referred to findings presented at the 77th Annual Conference of the Indian Psychiatric Society, which reported improvements in speech and communication in 48.95% of children, comprehension and cognitive engagement in 44.79%, eye contact in 20.83%, and behaviour regulation in 18%.
Vefa Lifesciences said it aims to remain at the forefront of evidence-based innovation while delivering meaningful social impact in the field of neurological healthcare.